Toll-like Receptor Agonists Are Unlikely to Provide Benefits in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Recurrent and metastatic head and neck cancer has limited treatment options and survival time is measured in months. Toll-like receptor agonists have been shown to improve tumor immune responses in preclinical studies and several clinical trials have now been performed. We performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Maddineni, Sainiteesh, Chen, Michelle, Baik, Fred, Divi, Vasu, Sunwoo, John B., Finegersh, Andrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486924/
https://www.ncbi.nlm.nih.gov/pubmed/37686661
http://dx.doi.org/10.3390/cancers15174386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486924/
https://www.ncbi.nlm.nih.gov/pubmed/37686661
http://dx.doi.org/10.3390/cancers15174386

Ejemplares similares